Exposure, time between exposure and VTE (days) | ORLS1 | ORLS2 | England | ||||||
---|---|---|---|---|---|---|---|---|---|
 | Obs | Exp | RR1 (95% CI) | Obs | Exp | RR1 (95% CI) | Obs | Exp | RR1 (95% CI) |
MS 0 to 90 | 10 | 8.1 | 1.25 (0.59 to 2.31) | 17 | 6.7 | 2.64 (1.51 to 4.33) | 212 | 112 | 1.95 (1.69 to 2.24) |
91+ | 96 | 43.7 | 2.23 (1.80 to 2.74) | 71 | 30.1 | 2.45 (1.90 to 3.13) | 1297 | 619 | 2.17 (2.05 to 2.30) |
Myxoedema 0 to 90 | 38 | 39.8 | 0.95 (0.66 to 1.32) | 126 | 95.9 | 1.48 (1.18 to 1.85) | 2617 | 2058 | 1.48 (1.41 to 1.56) |
91+ | 160 | 107 | 1.52 (1.29 to 1.79) | 305 | 245 | 1.32 (1.16 to 1.51) | 8487 | 7237 | 1.26 (1.22 to 1.29) |
Psoriasis 0 to 90 | 12 | 11.6 | 1.04 (0.53 to 1.83) | 15 | 6.5 | 2.41 (1.33 to 4.06) | 226 | 134 | 1.73 (1.51 to 1.98) |
91+ | 87 | 54.2 | 1.62 (1.29 to 2.00) | 38 | 26.5 | 1.45 (1.02 to 2.01) | 1092 | 679 | 1.64 (1.54 to 1.75) |
Rheumatoid arthritis: 0 to 90 | 52 | 61.7 | 0.83 (0.61 to 1.10) | 50 | 37.0 | 1.43 (1.03 to 1.95) | 1122 | 730 | 1.71 (1.60 to 1.83) |
91+ | 395 | 279.8 | 1.46 (1.31 to 1.62) | 231 | 156 | 1.60 (1.38 to 1.85) | 5703 | 3626 | 1.75 (1.70 to 1.81) |
SLE 0 to 90 | 5 | 1.4 | 3.64 (1.18 to 8.56) | 6 | 1.8 | 3.41 (1.24 to 7.75) | 111 | 27.4 | 4.15 (3.40 to 5.01) |
91+ | 21 | 6.5 | 3.25 (2.01 to 4.98) | 29 | 5.9 | 5.03 (3.35 to 7.27) | 525 | 148 | 3.61 (3.31 to 3.94) |